NewEdge Wealth LLC Raises Stake in Gilead Sciences, Inc. $GILD

NewEdge Wealth LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.3% in the first quarter, Holdings Channel reports. The firm owned 706,725 shares of the biopharmaceutical company’s stock after acquiring an additional 60,255 shares during the period. Gilead Sciences accounts for 1.2% of NewEdge Wealth LLC’s investment portfolio, making the stock its 14th biggest position. NewEdge Wealth LLC’s holdings in Gilead Sciences were worth $98,496,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of GILD. Brighton Jones LLC boosted its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $215,000. Sivia Capital Partners LLC lifted its position in shares of Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares in the last quarter. Ieq Capital LLC increased its holdings in Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after purchasing an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its stake in shares of Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the sale, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 77,000 shares of company stock worth $9,978,740 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GILD. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Truist Financial reduced their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Morgan Stanley dropped their target price on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. Rothschild & Co Redburn lowered their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Finally, The Goldman Sachs Group lifted their target price on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $158.33.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported that their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, a key step that supports upcoming regulatory filings and could position the regimen as a first-of-its-kind treatment. Article Title
• Positive Sentiment: Gilead said it will present new HIV research at AIDS 2026, including long-term efficacy and safety data for lenacapavir and results from its collaboration with Merck, reinforcing investor attention on its HIV franchise. Article Title
• Positive Sentiment: Gilead advanced a long-acting HIV regimen into a new Phase 3 head-to-head trial, signaling continued pipeline progress in one of the company’s most important growth areas. Article Title
• Neutral Sentiment: Gilead announced it will release second-quarter 2026 results on August 4, which keeps the stock in focus but does not provide new financial information yet. Article Title
• Neutral Sentiment: Market coverage noted that Gilead was trending and underperforming some peers intraday, suggesting mixed trading sentiment rather than a clear company-specific shock. Article Title
• Negative Sentiment: Leerink Partners downgraded Gilead to “market perform” from “outperform” and cut its price target to $127 from $146, which may be weighing on the shares. Article Title

Gilead Sciences Stock Up 0.0%

GILD opened at $130.34 on Thursday. The stock’s 50 day moving average price is $129.58 and its 200 day moving average price is $135.47. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The stock has a market cap of $161.83 billion, a P/E ratio of 17.76 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the previous year, the firm posted $1.81 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.